Premium
German psoriasis registry PsoBest: objectives, methodology and baseline data
Author(s) -
Augustin Matthias,
Spehr Christina,
Radtke Marc A.,
Boehncke WolfHenning,
Luger Thomas,
Mrowietz Ulrich,
Reusch Michael,
Strömer Klaus,
Wozel Gottfried,
Kiedrowski Ralph v.,
Rustenbach Stephan J.,
Purwins Sandra,
Reich Kristian
Publication year - 2014
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.12233
Subject(s) - medicine , psoriasis , adalimumab , ustekinumab , infliximab , etanercept , efalizumab , golimumab , psoriatic arthritis , discontinuation , comorbidity , dermatology , adverse effect , disease , rheumatoid arthritis
Summary Background The German psoriasis registry PsoBest records the long‐term efficacy, safety, patient benefit and treatment regimens of psoriasis. Patients and methods Patients with moderate or severe psoriasis are included in PsoBest when treatment with a conventional systemic agent or biologic is started for the first time. Observation time is five years. Standardized physician and patient case report forms are obtained every three to six months. Baseline data of patients included by 31 December 2012 are presented and compared to the national health care study PsoHealth 2007 (n = 2,009). Results 602 dermatology practices and clinics have been registered and 199 have recruited n = 2,556 patients (63 % by practices, 37 % by clinics). Initially, n = 808 received biologics (316 adalimumab, 34 efalizumab, 209 etanercept, 75 infliximab, 22 golimumab, 152 ustekinumab) and n = 1,651 conventional systemic therapy (928 fumaric acid esters, 518 methotrexate, 161 cyclosporine A, 191 other drugs or UV treatment). Compared to PsoHealth, patients in PsoBest had on average a higher disease severity (PASI 14.7 vs. 10.1; DLQI 11.0 vs. 7.5; EQ‐5D VAS 54.0 vs. 64.5), shorter disease duration (18.2 vs. 21.3 yrs.), lower age (47.3 vs. 51.5), higher rates of psoriatic arthritis (20.5 vs. 19.1 %) and nail psoriasis (55.0 vs. 35.6 %). On average patients receiving biologics were younger, more often male and had higher disease severity and comorbidity. Conclusions Patients in PsoBest represent patients with a high burden of disease.